Skip to main content

Table 3 Resolving on discrepance between the 18 HPV MALDI-TOF MS and the Roche Cobas 4800 assays by sequencing

From: Development of high-throughput genotyping method of all 18 HR HPV based on the MALDI-TOF MS platform and compared with the Roche Cobas 4800 HPV assay using clinical specimens

HPV genotype Disagreement of both assays Results of sequencing and genotyping on dis-concordant results of both assays Conc. rate (%) Results of sequencing and genotyping on dis-concordance
Conc. Dis-conc. Total
HPV16 MALDI-TOF MS+/Cobas- 16 6 22 72.7 6 (1), 11 (1), 52 (1), 54 (1), 81 (2), 82 (1), neg(2)
MALDI-TOF MS−/Cobas+ 12 7 19 63.2 6 (2), 40 (1), 42 (1), 43 (2), 52 (2), 58 (1), neg(2)
HPV18 MALDI-TOF MS+/Cobas- 2 1 3 66.7 neg(1)
MALDI-TOF MS−/Cobas+ 0 1 1 0 58 (1)
Other 12 HR HPV MALDI-TOF MS+/Cobas- 20 12 32 62.5 6 (2), 40 (2), 53 (7), 54 (1), 73 (1), 81 (2), neg(3)
MALDI-TOF MS−/Cobas+ 16 14 30 53.3 6 (2), 11 (2), 16 (4), 40 (1), 42 (2), 43 (1) 44 (1), 53 (2), 71 (1), 72 (1), 81 (3), 82 (2), neg(4)
  1. Conc. Concordance, dis-conc. Disconcordance, neg Negative